Sagimet Biosciences shares climb 29% after strategic shift to U.S. acne treatment
Updated
Updated · MarketWatch · Apr 27
Sagimet Biosciences shares climb 29% after strategic shift to U.S. acne treatment
7 articles · Updated · MarketWatch · Apr 27
The stock rose to $7.55 in premarket trading as Sagimet announced a U.S. Phase 3 trial of denifanstat for moderate to severe acne starting later this year.
This move follows successful Phase 3 trial results in China and marks a broader focus on dermatology, while the company seeks nondilutive funding for its MASH liver disease program.
Sagimet will pause further MASH clinical development until additional funding is secured, and its Chinese partner reported positive long-term safety and efficacy data for denifanstat in severe acne patients.
If the drug succeeded in China, why is another costly US trial needed?
With $175M raised, is the cash runway enough to get this drug to market?
Is pausing a promising liver drug to chase the acne market a smart pivot?
Can a new pill treat severe acne without Accutane's dangerous side effects?
Why did executives sell shares just before this major pivot and fundraising?
How does inhibiting a 'fatty acid' enzyme actually clear up skin acne?